Open AccessNeoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR
Author(s) -
Stéphanie A. Blankenstein,
Maartje W. Rohaan,
W. Martin C. Klop,
Bernies van der Hiel,
Bart A. van de Wiel,
Max J. Lahaye,
S. Adriaansz,
Karolina Sikorska,
Harm van Tinteren,
Ayşegül Sarı,
Lindsay G Grijpink-Ongering,
Winan J. van Houdt,
Michel W.J.M. Wouters,
Christian U. Blank,
Sofie Wilgenhof,
Johannes V. van Thienen,
A.C.J. van Akkooi,
John B.A.G. Haanen
Publication year - 2021
Publication title -
annals of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.153
H-Index - 309
eISSN - 1528-1140
pISSN - 0003-4932
DOI - 10.1097/sla.0000000000004893
Subject(s) - medicine , trametinib , dabrafenib , melanoma , interquartile range , stage (stratigraphy) , clinical endpoint , surgery , neoadjuvant therapy , mek inhibitor , cancer , oncology , vemurafenib , randomized controlled trial , metastatic melanoma , breast cancer , cancer research , mapk/erk pathway , paleontology , kinase , biology , microbiology and biotechnology
To evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in patients with unresectable locally advanced melanoma.